Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis
2009
Abstract
The differences in the pharmacokinetic measures of early systemic exposure between oral and subcutaneous routes support the view that lower and saturable intestinal absorption of oral MTX limits its bioavailability and efficacy within the range of standard doses used to treat children with JIA. In light of this evidence it can be recommended to use parenteral route of administration when MTX dose around above 10-15mg/m2 is needed to achieve sufficient response.